ARTICLE | Distillery Therapeutics
Cardiovascular
November 9, 2016 9:05 PM UTC
Patient sample and mouse studies suggest inhibiting HDLBP could help treat atherosclerosis in patients with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH). In 10 NAF...
BCIQ Target Profiles